Healthcare Stocks Long-Term Investors Should Buy Now
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: Fool
- Pfizer's Recovery Potential: Pfizer (PFE) previously achieved a staggering $100 billion in revenue, but has seen significant declines due to reduced demand for COVID products and patent expirations, with a current price-to-earnings ratio of only 9, making it attractive for long-term investors.
- Growth Driven by Acquisitions: Pfizer's acquisitions of Seagen and Metsera have provided it with commercialized drugs and late-stage candidates, positioning the company to enter the high-growth oncology and obesity drug markets, thereby laying the groundwork for future growth.
- UnitedHealth Group's Strategic Actions: UnitedHealth Group (UNH) has faced challenges from rising healthcare costs and increased service usage, but has implemented measures such as cutting certain plans and utilizing AI to streamline processes, which are expected to aid recovery and growth in the coming quarters.
- Competitive Advantage and Investment Opportunity: UnitedHealth's dual business model in health insurance and health services provides a solid competitive moat, and with a current price-to-earnings ratio of 15, it presents a fantastic buying opportunity for investors, especially amid market fluctuations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 27.570
Low
24.00
Averages
28.56
High
35.00
Current: 27.570
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics: A Dark Horse in the GLP-1 Market
- Market Potential: The GLP-1 weight loss market is projected to reach annual sales of $100 billion by the next decade, presenting a significant growth opportunity for Viking Therapeutics and its VK2735 candidate, especially with the potential launch of an oral version.
- Clinical Trial Progress: The injectable version of VK2735 is currently in phase 3 clinical trials, while the oral version completed phase 2 trials last year with highly promising initial results, laying a solid foundation for future commercialization.
- Acquisition Potential: Should VK2735 achieve commercial viability, Viking could become a takeover target in the biotech sector, with acquisition offers potentially reaching three times its current $4 billion market cap, reflecting strong market expectations for its future.
- Investment Risks and Opportunities: Viking's stock presents a binary risk, where the success or failure of VK2735 will directly impact its share price; despite the high risks, the potential rewards are equally substantial, necessitating careful position sizing by investors to navigate possible volatility.
See More
Viking Therapeutics' VK2735: A Dark Horse in GLP-1 Weight Loss Market
- Significant Market Potential: The GLP-1 weight loss market is projected to reach annual sales of $100 billion by the next decade, providing Viking Therapeutics' VK2735 with substantial market opportunities, particularly with the promising results expected from its oral version's clinical trials.
- Critical Clinical Trial Phase: The injectable VK2735 is currently in phase 3 clinical trials, while the oral version's phase 2 trial completed last year with promising initial results, which will directly impact Viking's stock performance depending on the outcomes of these trials.
- Acquisition Potential: Should VK2735 achieve commercial viability, Viking's market cap of approximately $4 billion could attract acquisition offers potentially reaching three times its current valuation, highlighting its appeal as a biotech stock.
- Risks and Opportunities: While the outlook for VK2735 is optimistic, the stock carries significant volatility risks; Viking's shares once approached $100 but currently trade around $32, necessitating careful risk-reward assessment by investors.
See More
Viking Therapeutics: A Dark Horse in the GLP-1 Market
- Market Potential: The GLP-1 weight loss market is projected to reach annual sales of $100 billion by the start of the next decade, providing Viking Therapeutics' VK2735 candidate with significant commercial opportunities, especially if an oral version is approved.
- Clinical Trial Progress: The injectable version of VK2735 is currently in phase 3 clinical trials, while the oral version completed phase 2 trials last year with promising initial results, which could significantly boost Viking's stock price.
- Acquisition Potential: Should VK2735 achieve commercial viability, Viking could become a takeover target in the biotech sector, with acquisition offers potentially reaching three times its current $4 billion market cap, reflecting high market expectations for its future.
- Investment Risks and Opportunities: Viking's stock presents a binary risk; the success or failure of VK2735 will directly impact its share price, and while the risks are considerable, the potential rewards are equally significant, necessitating careful position sizing by investors to manage possible volatility.
See More
Salesforce Stock Decline Amid Strong Performance Metrics
- Revenue Growth: Salesforce reported a 12% year-over-year revenue increase in Q4 2025, reaching $11.2 billion, which, despite a slowdown, remains impressive for a mature company with a market cap exceeding $170 billion, indicating sustained market demand.
- Future Revenue Commitments: The company disclosed $72 billion in remaining performance obligations (RPO) in Q4, a 14% year-over-year rise, which CEO Marc Benioff described as an 'incredible milestone', highlighting the stability of future revenues.
- Profitability Improvement: Salesforce achieved a GAAP operating margin of 20.1% and a non-GAAP operating margin of 34.1% in fiscal year 2026, nearing its highest levels ever, which boosts investor confidence in its financial health.
- Share Repurchase Plan: The announcement of a $50 billion share repurchase plan, following $12.7 billion in buybacks last fiscal year, reflects Salesforce's strategy to leverage its current attractive valuation to enhance shareholder returns, demonstrating confidence in future growth.
See More
Salesforce's Profitability Nears All-Time High
- Profitability Boost: Salesforce's GAAP operating margin reached 20.1% and non-GAAP operating margin stood at 34.1% in fiscal year 2026, indicating that the company's profitability is nearing its all-time high, which enhances investor confidence.
- Sustained Revenue Growth: In Q4 of fiscal year 2025, Salesforce's revenue grew 12% year-over-year to $11.2 billion, showing solid performance for a mature company with a market cap exceeding $170 billion, despite a slower growth rate compared to its past.
- Increase in Future Revenue Commitments: Salesforce reported total remaining performance obligations (RPO) of $72 billion in Q4, a 14% year-over-year increase, with CEO Marc Benioff calling this milestone
See More
EMA's CHMP Suggests Expanding Therapeutic Use for Hympavzi
- EMA Recommendation: The European Medicines Agency (EMA) has recommended the extension of the therapeutic indication for the drug HYM-PAV-ZI.
- Therapeutic Use: This extension aims to broaden the potential applications of HYM-PAV-ZI in treating specific medical conditions.
See More
Viking Therapeutics: A Dark Horse in the GLP-1 Market
- Market Potential: The GLP-1 weight loss market is projected to reach annual sales of $100 billion by the next decade, presenting a significant growth opportunity for Viking Therapeutics and its VK2735 candidate, especially with the potential launch of an oral version.
- Clinical Trial Progress: The injectable version of VK2735 is currently in phase 3 clinical trials, while the oral version completed phase 2 trials last year with highly promising initial results, laying a solid foundation for future commercialization.
- Acquisition Potential: Should VK2735 achieve commercial viability, Viking could become a takeover target in the biotech sector, with acquisition offers potentially reaching three times its current $4 billion market cap, reflecting strong market expectations for its future.
- Investment Risks and Opportunities: Viking's stock presents a binary risk, where the success or failure of VK2735 will directly impact its share price; despite the high risks, the potential rewards are equally substantial, necessitating careful position sizing by investors to navigate possible volatility.
See More
Viking Therapeutics' VK2735: A Dark Horse in GLP-1 Weight Loss Market
- Significant Market Potential: The GLP-1 weight loss market is projected to reach annual sales of $100 billion by the next decade, providing Viking Therapeutics' VK2735 with substantial market opportunities, particularly with the promising results expected from its oral version's clinical trials.
- Critical Clinical Trial Phase: The injectable VK2735 is currently in phase 3 clinical trials, while the oral version's phase 2 trial completed last year with promising initial results, which will directly impact Viking's stock performance depending on the outcomes of these trials.
- Acquisition Potential: Should VK2735 achieve commercial viability, Viking's market cap of approximately $4 billion could attract acquisition offers potentially reaching three times its current valuation, highlighting its appeal as a biotech stock.
- Risks and Opportunities: While the outlook for VK2735 is optimistic, the stock carries significant volatility risks; Viking's shares once approached $100 but currently trade around $32, necessitating careful risk-reward assessment by investors.
See More
Viking Therapeutics: A Dark Horse in the GLP-1 Market
- Market Potential: The GLP-1 weight loss market is projected to reach annual sales of $100 billion by the start of the next decade, providing Viking Therapeutics' VK2735 candidate with significant commercial opportunities, especially if an oral version is approved.
- Clinical Trial Progress: The injectable version of VK2735 is currently in phase 3 clinical trials, while the oral version completed phase 2 trials last year with promising initial results, which could significantly boost Viking's stock price.
- Acquisition Potential: Should VK2735 achieve commercial viability, Viking could become a takeover target in the biotech sector, with acquisition offers potentially reaching three times its current $4 billion market cap, reflecting high market expectations for its future.
- Investment Risks and Opportunities: Viking's stock presents a binary risk; the success or failure of VK2735 will directly impact its share price, and while the risks are considerable, the potential rewards are equally significant, necessitating careful position sizing by investors to manage possible volatility.
See More
Salesforce Stock Decline Amid Strong Performance Metrics
- Revenue Growth: Salesforce reported a 12% year-over-year revenue increase in Q4 2025, reaching $11.2 billion, which, despite a slowdown, remains impressive for a mature company with a market cap exceeding $170 billion, indicating sustained market demand.
- Future Revenue Commitments: The company disclosed $72 billion in remaining performance obligations (RPO) in Q4, a 14% year-over-year rise, which CEO Marc Benioff described as an 'incredible milestone', highlighting the stability of future revenues.
- Profitability Improvement: Salesforce achieved a GAAP operating margin of 20.1% and a non-GAAP operating margin of 34.1% in fiscal year 2026, nearing its highest levels ever, which boosts investor confidence in its financial health.
- Share Repurchase Plan: The announcement of a $50 billion share repurchase plan, following $12.7 billion in buybacks last fiscal year, reflects Salesforce's strategy to leverage its current attractive valuation to enhance shareholder returns, demonstrating confidence in future growth.
See More
Salesforce's Profitability Nears All-Time High
- Profitability Boost: Salesforce's GAAP operating margin reached 20.1% and non-GAAP operating margin stood at 34.1% in fiscal year 2026, indicating that the company's profitability is nearing its all-time high, which enhances investor confidence.
- Sustained Revenue Growth: In Q4 of fiscal year 2025, Salesforce's revenue grew 12% year-over-year to $11.2 billion, showing solid performance for a mature company with a market cap exceeding $170 billion, despite a slower growth rate compared to its past.
- Increase in Future Revenue Commitments: Salesforce reported total remaining performance obligations (RPO) of $72 billion in Q4, a 14% year-over-year increase, with CEO Marc Benioff calling this milestone
See More
EMA's CHMP Suggests Expanding Therapeutic Use for Hympavzi
- EMA Recommendation: The European Medicines Agency (EMA) has recommended the extension of the therapeutic indication for the drug HYM-PAV-ZI.
- Therapeutic Use: This extension aims to broaden the potential applications of HYM-PAV-ZI in treating specific medical conditions.
See More
